¡i¯S§O³ø¾É¡j |
¥_¨Ê¤¤ÂåÃĤj¾Ç®}§µ°Æ®Õªø²v¹Î³X°Ý¥»®Õ |
|
¥_¨Ê¤¤ÂåÃĤj¾Ç®}§µ°Æ®Õªø(¥k¤G)¡B°ò¦Âå¾Ç°|°¨¿P¥V±Ð±Â(¥ª¤@)¡B
°ê»Ú¥æ¬y³B±i¥ß¥°Æ³Bªø(¥ª¤G) |
¡@¡i¾Ç³N¥æ¬y¤¤¤ß/±ç¨|¥Á²Õªø °T¡j¥_¨Ê¤¤ÂåÃĤj¾Ç¬°¤¤°ê¤j³°¥|©Ò¦Ñ¤¤ÂåÃĤj¾Ç¡A³Ð«Ø©ó1956¦~¡A¬O°ß¤@¤@©Ò¶i¤J¤¤°ê°ê®a211¤uµ{«Ø³]ªº°ªµ¥¤¤ÂåÃÄ°|®Õ¡C¡]211¤uµ{¬°½ñ¤J21¥@¬ö¡A100¶¡«ÂIµo®i°ªµ¥°|®Õ¡^¡C¥_¨Ê¤¤ÂåÃĤj¾Ç®}§µ°Æ®Õªø²v¹Î¡A°ò¦Âå¾Ç°|°¨¿P¥V±Ð±Â¡]Âå¾Ç¥v±Ð±Â¡^¤Î°ê»Ú¥æ¬y³B±i¥ß¥°Æ³Bªø¡]¤¤Âå®ø¤Æ¾Ç¬ì±Ð±Â¡^¡A³X°Ý§Ú®Õ¡C¡@¡@
°Ñ¥[®y½Í·|¦³±i¥Ã½å°Æ®Õªø¡B¤¤Âå¾Ç¨t¥D¥ô°ª©|¼w¡B¾Ç¤h«á¤¤Âå¾Ç¨t¥D¥ô³¯¥ß¼w¡B°ê»Ú¾Ç³N¥æ¬y¤¤¤ß¥D¥ôÃö¶WµM¡B±ç¨|¥Á¡B±i¤j¬°¡BÁ¹Ůe¡B¤¤Âå¾Ç°|±Ð®vð®RÄå¡B³¯®®¥Í¡B³¯¥Ã²»¡BªLºû«i¡B±äºa¿o¡B¤¤Ãľǰ|±i¥Ã¾±»Pªþ³]Âå°|°w¨b¬ì§õ¨|¦Ú¥D¥ô¡B³\ª@®p¤Î³Å¤¸Áo¡C
¥_¨Ê¤¤ÂåÃĤj¾Ç¦b®Õ¥Í10,581¤H¡A§Y¥»¬ì¥Í6,614¤H¡A±M¬ì¥Í1,406¤H¡AºÓ¤h¥Í1,992¤H¤Î³Õ¤h¥Í569¤H¡C¥Ñ©óÂù®Õ¦Û1998¦~¦³Ã±¬ù¬°©n©f¾Ç®Õ¡A¥ý«áÁ|¿ì®ü®l¨â©¤¤¤ÂåÃľdzN¬ã°Q·|¡A¦@4©¡¡A¦]¹J³{SARS¦Ó°±¿ì¡C®}°Æ®Õªø§Æ±æ¦Û¤µ¦~°_¦A«×«ì´_Á|¿ì¡C¥_¨Ê¤¤ÂåÃĤj¾Ç·s¥ô®Õªø°ª«äµØ±Ð±Â¡A±N²v¹Î°Ñ¥[¥»®Õ50¶g¦~®Õ¼y¼y¨å¤Î³X°Ý§Ú®Õ¡C
¡i¸ê®Æ¨Ó·½:¾Ç³N¥æ¬y¤¤¤ß¡j
¡@ |
|
°ê»Ú§ß½üªÀ¥æ´«¹Îû³X°Ý§Ú®Õ |
|
¥k¤¤¡G³¯¤@¶¯¸³¨Æ¡B¥ª¤¤¡G¨Ó¦Û¬ü°êªü©Ô´µ¥[Rebecca Kleinschmid |
¡@¡i¾Ç³N¥æ¬y¤¤¤ß/±ç¨|¥Á²Õªø °T¡j97¦~3¤ë26¤é¥»®Õ³¯¤@¶¯¸³¨Æ¡]¥L¬OÃľǨt²Ä4©¡®Õ¤Í¡^¡A³¦P°ê»Ú§ß½üªÀGSE¡]¹ÎÅé¬ã¨s¥æ´«pµe¡^±µ«Ý¹Î¥x¤¤¥D©e¤ý¹Å»Ê¥ý¥Í¤Î¥x¤¤§ß½üªÀÁp½Ë¥D©e±i¤ì¤ô¥ý¥Í¡A±a»â¬ã¨s¥æ´«pµeªº¤@¦ì¨Ó¦Û¬ü°êªü©Ô´µ¥[¹ÎûMs. Rebecca Kleinschmidt¡A¥Ñ©ó¹ï©ó§Ú°êÂåÀøºÞ²z¦³¿³½ì¡A¯S¨Ó§Ú®Õ°ÑÆ[¡C
¸g¥Ñ¥»®Õ¾Ç³N¥æ¬y¤¤¤ß±ç¨|¥Á²Õªø³¦P¡A°Ñ³X¥»®Õ¡C¨Ó»«¦b¥ß¤Ò¤j¼Ó²Ä¤T·|ij«ÇÆ[¬Ý¥»®Õ¦h´CÅé²³ø¨Ã»P±i¥Ã½å°Æ®Õªø¥æ¬y®y½Í¡C¤§«á¨Ó»«°ÑÆ[¤¤ÃÄ®i¥ÜÀ]¡BÃĶé©M¤¤¦èÂåµ²¦XªvÀøªù¶E¡C¹ï©ó±q»»»·ªº¬ü°êªü©Ô´µ¥[¦Ó¨ÓªºMs. Rebecca Kleinschmidt¦Ó¨¥¡A¤¤Âå©M¤¤ÃĬJ¯«¯µ¦Ó¤S¦³½ì¡C¤§«á¨Ó»«¦A°ÑÆ[¥ß¤ÒÂåÀø¤j¼Ó©M¤Åv®Õ°Ï¤§Àù¯g¤¤¤ß»P«æ¶E¤¤¤ß¡C¦¹¦æÅýMs. Rebecca Kleinschmidt¹ï¥xÆWªºÂåÀø¨t²Î¤Î°·«O¨î«×¦³¤F°ò¥»ªº»{ÃÑ¡C
§Ú®Õªº¾Ç¥Í¥X°ê¶iסA°£¥Ó½Ð±Ð¾Ç¨ô¶Vpµeµ¥¥~¡A¤]¥i³z¹L°ê»Ú§ß½üªÀ¡B·à¤l·|µ¥¦³¥æ´«¾Ç¥Ípµe©Î¬O¥Ó½Ð¼ú¾Çª÷¥X°ê¾Ç²ß¡C
¡i¸ê®Æ¨Ó·½:¾Ç³N¥æ¬y¤¤¤ß¡j
¡@ |
|
¡iµJÂI·s»D¡j |
ºë¯«¯e¯f·sÀøªkªº¬ãµo -- ¦ÙÓi»Ä |
¡@¡iÂå¾Ç°|/ÂÅ¥ý¤¸¥D¥ô °T¡jºë¯«¬ìÂÅ¥ý¤¸±Ð±Âªº¬ã¨s¹Î¶¤»P¬ü°ê UCLA Dr. Guochuan E. Tsai ©Ò¦X§@¬ãµoªº°w¹ïºë¯«¯e¯f·sÀøªk¡]¦ÙÓi»Ä¡Asarcosine¡^¡A³ÌªñÀò±o°ê»Ú¶¡¶i¤@¨BªºªÖ©w¡A·sªº½×¤å©ó2008¦~1¤ë©óBiological Psychiatry µoªí¡A¨ÃÀò·í´Áµû½×½×¤å¡]µû½×ªÌ Javitt ³Q¬ì¾Ç¤HÂø»xÅA¬°·í¥Nºë¯«¤Àµõ¯g±Æ¦W²Ä¤@ªº¬ã¨sªÌ¡^±À±R¬°¤U¤@¥@¥N³Ì«nªººë¯«¤Àµõ¯g·sÀøªk¡AÂø»x¥Xª©ªÀ¡]Elsevier¡^¨Ã¥D°Êµo¥X·s»D½Z¡AÄÄz¦¹Àøªk¤§«n©Ê¡C¦ÙÓi»Ä¬O¤@ºØ¦s©ó¹ª«¤Î¤HÃþ¤j¸£ªºÓi°ò»Ä¡A¥Dn¥i§@¬° glycine transporter §í¨î¾¯¡A¤]´N¬O¥i¥H´£°ª¬ðIJ¶¡»Øglycineªº¿@«×¡C¥Ø«e¡A§Ú̦b¦ÙÓi»Ä³oÓ»â°ìªº¬ã¨s¿W¨B¥þ²y¡A2004¦~°_Á`¦@µoªí¥|½g¬ÛÃö¤å³¹¡A¤@½gµoªí©óArchives of General Psychiatry (SCI impact factor 13.94)¡B¥t¤T½gµoªí©óBiological Psychiatry (SCI impact factor 7.2)¡C
ºë¯«¤Àµõ¯g¬O³Ì¥Dnªººë¯«¯e¯f¤§¤@¡A¶Ç²ÎªvÀøÃĪ«ªº°Æ§@¥Î¤j¡A±wªÌªº¿íÂåÅñ©Ê§C¡A¦Ó¦b§ïµ½³h»y¯g¡BµL°Ê¾÷¡BªÀ¥æ°hÁYµ¥©Ò¿×ªºt©Ê¯gª¬¤W®ÄªG¤£¹ü¡C§Y¨Ï·s«¬ÃĪ«¡A¨ÌµM¦³³\¦h±wªÌ®ÄªG¤£¹ü¡A¤]¥i¯à¦³¶ÝºÎ©Î¥NÁ²§±`¡]¦pªÎD¡B¿}§¿¯f¡B¦å¯×ªÕ»PÁx©T¾J¤W¤É¡^µ¥°Æ§@¥Î¡C
ÂÅÂå®vªº¦ÙÓi»Ä¬ã¨s¬°°ê®a½Ã¥Í¬ã¨s°|»P°ê¬ì·|©Ò¸g¶O¤ä«ù¤§¬ã¨spµe¡Cªì¨Bµo²{¦¹Ói°ò»ÄªºÀø®Ä»P¦w¥þ©Ê»á¨Î¡A·íµM¡A¥Ø«e³o¤´³B©óÁ{§É¬ã¨s¶¥¬q¡A«DÁ{§ÉÂå®v¥i¥H³w¦æ³B¤è¡C¦ý¥Ñ©óglycine¬°NMDA¨üÅ骺co-agonist¡A¦¹¤@µo²{¤]¤ä«ùºë¯«¤Àµõ¯g°£¦h¤ÚÓi°²»¡¥~¡ANMDA¥\¯à¤£¨¬¥i¯à¤]§êºt«n¨¤¦â¡C¤é¥»»P¬ü°êªº¾ÇªÌ³Ìªñ¤]µo²{¡Aºë¯«¤Àµõ¯g±wªÌ¦å²M©Î¸£¯áÅè²G¤¤¤@¨Ç»PNMDA¯«¸g¶Ç¾É¬ÛÃöªºÓi°ò»Ä¿@«×¸û§C¡A³o¨ÇÓi°ò»Ä¹ï©ó°O¾Ð¤O¡B±Mª`¤O¡B©â¶H«ä¦Ò¡Bpµe¯à¤Oµ¥»{ª¾¥\¯àÁ|¨¬»´«¡A¦Ó³o¨ÇÓi°ò»Äªº¤í¯Ê³Q»{¬°¥i¯à¬Oºë¯«¤Àµõ¯gªº«n¯f¦]¡C
¡i¸ê®Æ¨Ó·½¡GÂå¾Ç°|¡j
ÂÅ¥ý¤¸ (Lane, Hsien-Yuan)
¾Ç¾ú (Education)¡G
¥x¥_Âå¾Ç°|Âå¾Ç¨tÂå¾Ç¤h [1980-1987]
°ê¨¾Âå¾Ç°|»P¤¤¥¡¬ã¨s°|¦X¿ì¥Í©R¬ì¾Ç¬ã¨s©Òõ¾Ç³Õ¤h [1995-2000]
²{¾ (Present Positions)¡G
¤¤°êÂåÃĤj¾Çªþ³]Âå°| ºë¯«Âå¾Ç³¡¥D¥ô
¤¤°êÂåÃĤj¾ÇÂå¾Ç°| ºë¯«Âå¾Ç¬ì¥D¥ô/Á{§ÉÂå¾Ç¬ã¨s©Ò ±Ð±Â
°ê¥ß¦¨¥\¤j¾ÇÂå¾Ç°| ¦æ¬°Âå¾Ç©Ò Ý¥ô±Ð±Â
°ê®a¬ì¾Ç©eû·|¾Ç³N¼ú¶µ (National Science Council Awards, Taiwan):
¤Aµ¥¬ã¨s¼ú [1996, 1997, 1998]
¥Òµ¥¬ã¨s¼ú [1999, 2000]
¬ã¨s¼ú¡]A¼ú¡^ [2005-2008]
¨ä¥L¾Ç³N¼ú¶µ (Other Awards):
¥xÆWºë¯«Âå¾Ç·|ºë¯«¤Àµõ¯g¬ã¨s½×¤å¼ú [2000, 2003, 2004, 2005; 2006, 2007]
¤¤°êÂåÃĤj¾Ç³Ç¥X¬ã¨s±Ð®v¼ú [2005, 2008-2010]
¦³«Ö¬ì§Þ½×¤å¼ú [2006]
¤¤¥¡¬ã¨s°| °ê®a°ò¦]Åé¬ã¨s¤¤¤ß °ò¦]ÂåÃĬã¨sÁ{§É¤¤¤ß User Committee
2004-present
°ê®a½Ã¥Í¬ã¨s°| ºë¯«¯e¯fº[ÃĪ«ÀÝ¥Î²Õ ºë¯«¤Àµõ¯gÃĪ«ªvÀø¦@ÃÑ·|ij ¥l¶°¤H
2005-present
½Ã¥Í¸pÃÄ«~¿Ô¸ß©eû
2006-present
¸g¾ú (Positions Held)¡G
¥x¥_¥«¥ßÀø¾i°|¦í°|Âå®v [1989-1992]
¥x¥_¥«¥ßÀø¾i°|Á`¦í°|Âå®v [1992-1993]
¥x¥_¥«¥ßÀø¾i°|¥DªvÂå®v [1993-2000]
¥x¥_Âå¾Ç°|Âå¾Ç¦ÍÝ¥ôÁ¿®v [1997-2000]
°]¹Îªk¤H¦ò±Ð·OÀÙºî¦XÂå°|¨¤ßÂå¾Ç¬ì¥DªvÂå®v[2000-2002]
·OÀÙ¤j¾Çºë¯«Âå¾Ç¬ìº[¯«¸g¬ì¾Ç¬ã¨s©Ò§U²z±Ð±Â[2000-2002]
¤¤°êÂåÃĤj¾Çªþ³]Âå°| ªÀ°Ïºë¯«¬ì¥D¥ô [2002-2003]
¤¤°êÂåÃĤj¾Çªþ³]Âå°| ºë¯«Âå¾Ç³¡¥D¥ô [2004-2006]
¤¤°êÂåÃĤj¾Ç ºë¯«Âå¾Ç¬ì§U²z±Ð±ÂÝ¥D¥ô [2002-2003]
¤¤°êÂåÃĤj¾Ç ºë¯«Âå¾Ç¬ì°Æ±Ð±ÂÝ¥D¥ô [2004-2006]
¤¤°êÂåÃĤj¾Ç Âå¾Ç¬ã¨s©Ò ©Òªø [2005-2006]
°ê¥ß¦¨¥\¤j¾ÇÂå¾Ç°| ¦æ¬°Âå¾Ç©Ò/ºë¯«¬ì °Æ±Ð±Â [2006-2007]
°ê¥ß¦¨¥\¤j¾ÇÂå¾Ç°|ªþ³]Âå°| ºë¯«³¡ ¥DªvÂå®v [2006-2007]
¤¤¥¡¬ã¨s°| ¥Íª«Âå¾Ç¬ì¾Ç¬ã¨s©Ò Ý¥ô°Æ¬ã¨sû [2006-2007]
°ê»Ú¾Ç³N´Á¥Z½sªÌ (Editor)¡G
2004-2007, Psychiatry and Clinical Neuroscience
2007-present, The Open Nitric Oxide Journal
°ê»Ú¾Ç³N´Á¥Z¼f½ZªÌ (Reviewer)¡G
1998, The Journal of Clinical Psychiatry
1999, The Journal of Clinical Psychiatry (2 papers)
2001, The Journal of Clinical Psychiatry
2002, The Journal of Clinical Psychiatry (2 papers)
2003, Biological Psychiatry
2004, Journal of Clinical Psychopharmacology (3 papers)
2005, Prog Neuropsychopharmacol & Biol Psychiatry (2 papers)
2005, Acta Pharmacologica Sinica
2005, The Journal of Nutritional Biochemistry
2005, Biological Psychiatry (2 papers)
2006, World Journal of Biological Psychiatry
2006, Journal of Formosan Medical Association (2 papers)
2006, Chinese Journal of Physiology
2006, Psychiatry Research
2006, Journal of Clinical Psychopharmacology (3 papers)
2006, Future Neurology
2006, Journal of Affective Disorder
2007, Journal of Formosan Medical Association (2 papers)
2007, BMC Psychiatry
2007, Comprehensive Psychiatry
2007, Human Psychopharmacology: Clinical and Experimental
2007, Journal of Biomedical Science
2007, World Journal of Biological Psychiatry
2007, The Journal of Nutritional Biochemistry
2007, The Pharmacogenomics Journal
2007, Pharmacogenomics
2007, Journal of Psychopharmacology
2007, Biological Psychiatry (3 papers)
2008, Journal of Psychiatry Research
2008, Lipids in Health and Disease
2008, Journal of Formosan Medical Association
2008, World Journal of Biological Psychiatry
2008, Personalized Medicine
2008, Pharmacogenomics
2008, Journal of Clinical Psychopharmacology
°ê»Ú¾Ç³N·|ij¥D«ù¤H (Invited Session Leader)¡G
2001, Session leader for the ¡§Acute Management of Schizophrenia¡¨ at the third Asia Pacific Psychopharmacology Workshop, June 1-2, 2001, Phuket, Thailand
°ê»Ú¾Ç³N·|ijÀ³ÁܺtÁ¿¤H (Invited Speaker)¡G
2007, Invited speaker for the symposium ¡§Current status and future perspectives on clinical trials of schizophrenia in East Asian countries¡¨ at the World Psychiatric Association Regional Meeting in Seoul, Korea, April 18-21, 2007.
2008, Invited speaker for the symposium ¡§Time course of the antipsychotic effect¡¨ for the inaugural meeting of the Schizophrenia International Research Society in Venice, June 21-25, 2008.
¬ü°êNARSAD¬ã¨spµe¦@¦P¥D«ù¤H
Evaluating sarcosine, a glycine uptake inhibitor, for cognition enhancement in schizophrenia
(NARSAD #12537-01) (2006/9/16-2008/9/15)
°ê®a½Ã¥Í¬ã¨s°|¾ã¦X«¬¬ã¨spµe¥D«ù¤H (NHRI Study Project):
1. Etiology and treatment of attention deficit in schizophrenia (National Health Research Institutes: NHRI-EX-91-9134PI, NHRI-EX-92-9134PI, NHRI-EX-93-9134PI)
2. NMDA hypofunction of schizophrenia: diagnosis and treatment (NHRI-EX-94-9405PI, NHRI-EX-95-9405PI, NHRI-EX-96-9405PI, NHRI-EX-97-9405PI, NHRI-EX-98-9405PI)
°ò¦]ÅéÂå¾Ç°ê®a«¬¬ì§Þp¹º¥D«ù¤H (National Research Program for Genomic Medicine):
1. Depression patients: Chinese medicine viewpoints and mRNA expressions in peripheral lymphocytes (94DOH004; CCMP94-RD-041; CCMP94-RD-041-1) (2005/5 ¡V 2007/4)
¥Í§Þ¤¤¤ß¡u«Ø¥ßÂàĶÂå¾ÇÁ{§É¬ã¨s¡vpµe¥D«ù¤H¡]Development Center for Biotechnology¡^
1. N-methylglycine (Sarcosine) treatment for depression
(DOH95-TD-B-111-TM002) (2006/1-2006/12)
°ê¬ì·|¬ã¨spµe¥D«ù¤H (NSC Study Projects):
1. Risperidone and clozapine treatment in treatment-resistant schizophrenia (the first year) (National Science Council: NSC-87-2314-B-109-003)
2. Risperidone and clozapine treatment in treatment-resistant schizophrenia (the second year) (NSC-88-2314-B-109-002).
3. Risperidone and clozapine treatment in treatment-resistant schizophrenia (the third year) (NSC-89-2314-B-109-002)
4. N-methyl-D-aspartate receptor modulation and schizophrenia (the first year) (NSC-89-2314-B-320-023)
5. N-methyl-D-aspartate receptor modulation and schizophrenia (the second year) (NSC-90-2314-B-320-003)
6. N-methyl-D-aspartate receptor modulation and schizophrenia (the third year) (NSC-91-2314-B-039-033)
7. Multiple receptor hypothesis of atypical antipsychotics ¡V A novel pharmacogenetic study model (NSC-92-2314-B-039-017)
8. Multiple receptor hypothesis of atypical antipsychotics ¡V A novel pharmacogenetic study model (NSC-93-2314-B-039-003) (the second year)
9. NMDA receptor modulation and refractory schizophrenia: targeting at glycine transporter (NSC-93-2314-B-039-023)
10. NMDA enhancers for schizophrenia treatment (NSC-94-2314-B-039-026, NSC-95-2314-B-006-119, NSC-96-2314-B-039-002)
11. NMDA modulation in schizophrenia: long-term efficacy of glycine transporter I inhibitor (NSC-95-2314-B-006-118-MY3)
½Ã¥Í¸p¡u¼ú§UÂåÀø¾÷ºc¤§Âå¨Æ¤Hû±q¨ÆÁ{§É¬ã¨s¡vpµe¡]95¦~«×¡^
½Ã¥Í¸p¬ã¨spµe¥D«ù¤H (Study Projects of Department of Health, Executive Yuan):
1. Suicide survivors: predictors and coping strategies (DOH-93-TD-M-113-036)
2. Depression: genotypes and phenotypes from the viewpoints of psychiatry and Chinese medicine
(Committee on Chinese Medicine and Pharmacy CCMP93-RD-050)
¡@ |
|
|
·¨½å´f²Õªø¥DÁ¿½è©Ê³X½Í¤èªk--§Þ¥©»Pµ¦²¤ |
|
|
·¨½å´f²Õªø»P°Ñ»P§Ó¤u¦X¼v |
·¨½å´f²ÕªøÁ¿±Â¡u³X½Í¥»½è»P©w¸q¡v |
|
|
·¨½å´f²ÕªøÁ¿z¡u³X½Í§Î¦¡¡v |
·¨½å´f²ÕªøÁ¿±Â¡u¦p¦ó¾ã²z³X½Í¬ö¿ý¡v |
¡@¡i¥_´ä¤À³¡ ±Ð¾Ç¨ô¶Vp¹º¿ì¤½«Ç/¿½¨q¥c °T¡j½è©Ê³X½Í¬OªÀ·|¬ì¾Ç¬ã¨s¤¤³Ì¼sªx¹B¥Îªº¦¬¶°¸ê®Æªº¤èªk¤§£¸¡A¥DnµÛ«©ó¨ü³XªÌÓ¤HªººA«×¡B¥Í¬¡»P¸gÅ窺³¯z¡CÂǵۻP¨ü³XªÌ©¼¦¹ªº¹ï¸Ü¡A¬ã¨sªÌ±o¥HÀò±o¤F¸Ñ¤Î¸ÑÄÀ¨ü³XªÌÓ¤H¹ïªÀ·|¨Æ¹êªº»{ª¾¡C
½Òµ{¶i¦æ¤è¦¡¬OÂǥѤ¬°Ê¦¡ªº¬ã²ß»P¹ê¨Ò¸Ñ»¡¡A³z¹L¾Ç²zªº«e¾É¸Ñ»¡»PÁô³ëªº»¡©ú¡A±a»â§Ó¤u̶i¤J½è©Ê³X½Íªº¥@¬É¡A´Á¨Ï§Ó¤u̱q¤¤¾Ç²ß³X½Í¤èªkªº§Þ¥©»Pµ¦²¤¡C
½Òµ{¤º®e¡G
¡·³X½Íªº¥»½è»P©w¸q
¡·³X½Íªº¼Ò¦¡
¡·³X½Íªº¶¥¬q ¡]¶}©l³X½Íªº¤èªk¡B´£°Ýªº¤èªk¡Bµ²§ô³X°Ýªº¤èªk¡B³X½Í°O¿ý¡^
¡·¨Ï³X½Í¦¨¥\ªºì«h¡]¦³®Ä³X½Íªº¦]¯À¡^
¡·³X½Í®É¥i¯àµo¥Íªº¿ù»~
¡·°Ñ»P§Ó¤u¤H¼Æ¡G¨â±è¦¸¦@208¤H¦¸
¡@
|
¤é´Á |
®É¶¡ |
Á¿ÃD |
|
²Ä
¤@
±è
¦¸ |
3/18¡]¤G¡^ |
17¡G20-19¡G00 |
½è©Ê³X½Í¤èªk--
§Þ¥©»Pµ¦²¤¡]¤@¡^ |
·¨½å´f²Õªø
¡]102±Ð«Ç¡^ |
3/25¡]¤G¡^ |
17¡G20-19¡G00 |
½è©Ê³X½Í¤èªk--
§Þ¥©»Pµ¦²¤¡]¤G¡^ |
²Ä
¤G
±è
¦¸ |
3/19¡]¤T¡^ |
17¡G20-19¡G00 |
½è©Ê³X½Í¤èªk--
§Þ¥©»Pµ¦²¤¡]¤@¡^ |
3/27¡]¥|¡^ |
17¡G20-19¡G00 |
½è©Ê³X½Í¤èªk--
§Þ¥©»Pµ¦²¤¡]¤G¡^ |
|
|
¤û¼V¤å¤Æ±´³X |
|
|
§Ó¤u̦b¡u²Â´ä1¸¹¡v¤W¦X¼v |
§Ó¤u»P¥_´äÂíÂíªø®}©¾¹ý¦X¼v |
|
|
¦Ñ·Ý·Ý¸ÑÄÀ100¦~¾ú¥vªº¤â¹qµ©µo¥úì²z |
¼ö¤ß¦ÑÁóÁ¿¸Ñ¡u¹ÆQµP¡vªº¥Ñ¨Ó |
¡@¡i¥_´ä¤À³¡±Ð¾Ç¨ô¶Vp¹º¿ì¤½«Ç/¿½¨q¥c °T¡j¥_´ä¤û¼V¦ì©ó¥_´ä¤j¾ô·Ë¯`¡A¶§¾ä¨C¦¯ 3¡B6¡B9 ¶}¥«¡A¬O¥xÆW¦´Á³W¼Ò³Ì¤jªº¤û°¦»°¶°¥«³õ¡A¦p¤µ³vº¥¨S¸¨ÂàÅܦ¨¦U¦æ¦U·~¡B³c½æÂø³fªº¾ÚÂI¡C±Ð¾Ç¨ô¶VpµeÂǥѱa»â§Ó¤u°ÑÆ[¥_´ä·Ë¡B¤û¼V¤Î¥_´äÂí¶Ç²Î²£·~°Ó®a¡AÅý§Ó¤uÅé·|¦´Á¥_´ä·Ë¤§¤jªe¤å¤Æ¾ú¥v²W·½¡AÁA¸Ñ¶Ç²Î²£·~¤§¿³°I¡A«ä¦Ò³Ð·N¹B¥Î©ó¶Ç²Î²£·~ªº·s«´¾÷¡AÅý¸gÀÙµo®iªº¦P®É¡A¤]¯à«O«ùÀu¨}ªº¶Ç²Î¯S¦â¡C
°Ñ»P§Ó¤u¦b¤û¼V¥«¶°¨£¨ì¦UÃþªºÅu°Ó´ºÆ[¡A¦p¶Ç²Î¥s½æÃÀ§Þ¡B¥jª«°Â°â¡B©úµP±¡³ø¯¸¡Kµ¥¡A³o¨Ç³£¬O¦b¥±`¥«¶°©Ò¤£¯à¨£ªº¡A¤]Åé·|¤£¦P±»ªªº¥_´ä
¡i¸ê®Æ¨Ó·½¡G¥_´ä¤À³¡±Ð¾Ç¨ô¶Vp¹º¿ì¤½«Ç¡j
¥DÁ¿¤H¡Gùªr¬x¥ý¥Í
¡·¥_´ä·Ëµo·½»P¬y°ì
¡·ªe¬y¤å¤Æ»P¤H¤å´ºÆ[
¡·¤û¼V¥«¶°¤§¤µ©õ
¡·¤û¼V°Ó®a¸ê®Æ¦¬¶°»P°ÑÆ[
¡·¥_´ä¤ô¶ð²¤¶
¡·§»¯q³Âªo¼t¾ÉÄý
°Ñ»P§Ó¤u¡G¦@41¤H¦¸
97¦~3¤ë19¤é |
¤º®e |
|
8¡G30-10¡G00 |
¡]¼¦Ëµ¹C¥_´ä·Ë¡^
Á¿ÃD¡G
¥_´ä·Ëªe¹D¾ú¥v»P¤û¼V¤å¤Æµo®i |
ùªr¬x¥ý¥Í
¡]´_¿³ÅK¾ô¡B¥_´ä·Ë¡^ |
10¡G00-12¡G00 |
¤û¼V¤å¤Æ¸ê®Æ¦¬¶°»P°Ó®a±Ä³X |
ùªr¬x¥ý¥Í
¡]¥_´ä¤û¼V¡^ |
¡@
97¦~3¤ë29¤é |
¤º®e |
Á¿®v/¦aÂI |
8¡G30-11¡G00 |
Á¿ÃD¡G
¥_´ä·Ëªe¹D¾ú¥v»P¤û¼V¤å¤Æµo®i
¡]°Ó®a¸ê®Æ¦¬¶°¡^ |
ùªr¬x¥ý¥Í
¡]¥_´ä·Ë¡B¥_´ä¤û¼V¡^ |
11¡G00-11¡G20 |
°ÑÆ[§»¯q³Âªo¼t |
ùªr¬x¥ý¥Í |
11¡G20-11¡G50 |
¥_´ä¤ô¶ð²¤¶ |
ùªr¬x¥ý¥Í |
11¡G50-12¡G20 |
°ÑÆ[ºÖ¦wÀn¦×¶ºÀ] |
ùªr¬x¥ý¥Í |
|
|
|
¡i¥Í©R¬ì¾ÇÁ¿®y¶é¦a¡j |
²{¥N¥Íª«Âå¾ÇÁ¿®y |
|
|
´ö»Êõ±Ð±Â |
´ö»Êõ±Ð±Â»P¦Ñ®v®y½Í |
|
|
²{³õ¦Ñ®v»P¾Ç¥Í¿ãÅDÅ¥Á¿ |
Á¿®y»P¾Ç¥Í®y½Í |
¡@¥D¿ì³æ¦ì¡GÂå¾Ç°| Âå¾Ç¨t¡B°ò¦Âå¾Ç¬ã¨s©Ò¡BÁ{§ÉÂå¾Ç¬ã¨s©Ò¡BÀù¯g¥Í·N¾Ç¬ã¨s©Ò¡B¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò
¥Ø ¼Ð¡G¥»Á¿®y¥Dn¬°¨ó§U¾Ç¥Í±µÄ²¤£¦P¥Í©R¬ì¾Ç»â°ì¤§³Ì·sµo®i¤Î¨ä«äºû¼Ò¦¡¡A¥Ñ¦U©ÒÁܽЮե~¥Íª«Âå¾Ç»â°ì¾ÇªÌºtÁ¿¡A¨Ã»PÂå¾Ç°|¬ã¨s¥Í¤Î¦³¿³½ì°Ñ»Pªº±Ð®v®y½Í¡AÂÇ¥H´£ª@±Ð¾Ç»P¬ã¨s¡C
®É ¶¡¡GW5 12:00-14:30(12:00-12:30ÁܽФ§Á¿®y»P±Ð®v¥ÎÀ\¤Î®y½Í¡B12:30-13:30 ÁܽФ§Á¿®yºtÁ¿¡B13:30-14:00ºtÁ¿«áQ&A¡B14:00-14:30ÁܽФ§Á¿®y»P¾Ç¥Í®y½Í)
²Ä¤G³õ¡G´ö»Êõ±Ð±Â: Substratum rigidity, Calcium, Autophagy and Apoptosis
®É¶¡¡G97¦~3¤ë4¤é¬P´Á¤12:00~14:30
Á¿®y¡G´ö»Êõ±Ð±Â(¦¨¥\¤j¾Ç¥Í²z©Ò±Ð±Â¡A±Ð°Èªø)
Á¿ÃD¡GSubstratum rigidity, Calcium, Autophagy and Apoptosis
ºtÁ¿ºKn¡G
Collagen-gel-induced apoptosis was inversely correlated with substratum rigidity. Low-substratum- rigidity collagen-gel-induced apoptosis was neither prevented by Bcl-2 nor preceded by mitochondrial release of cytochrome c. Low substratum rigidity activated c-Jun N-terminal kinase (JNK), but it also rapidly downregulated c-Jun and triggered persistent aberrant expression of c-Fos. Either reduction of c-Jun expression or overexpression of c-Fos has been shown to induce apoptosis in several epithelial cells. Inhibiting low-substratum-rigidity-induced JNK activation prevented aberrant c-Fos expression, but only partially blocked low-substratum-rigidity-induced apoptosis. Low rigidity of collagen gel induced apoptosis in epithelial cells within 24 h, whereas it induced an increase in intracellular Ca++ ([Ca++]i) and endoplasmic reticulum Ca++ overloading within 1 h, which lead to cell membrane flipping as assessed by positive Annexin V staining. In addition, low substratum rigidity triggered deregulation of AP-1 protein family, which eventually resulted in apoptosis within 24 h, as reflected by the presence of DNA and nuclear fragmentation. In order to understand the sequential cell biological events between membrane flipping and nuclear fragmentation as triggered by low substratum rigidity, I would like to know whether the formation of autophagy is involved in this process. We found that low substratum rigidity of collagen gel induced the formation of autophagy in normal epithelial but not transformed cells within 8 h. Inhibition of autophagy formation augmented nuclear fragmentation without alteration of membrane flipping at the early phase. Reduction of [Ca++]i by calcium chelators or channel blockers prevented low rigidity-induced formation of autophagy. In contrast, treatment of Ca++ ionophore induced formation of autophagy, suggesting that low substratum rigidity-induced intracellular Ca++ overload leads to the formation of autophagy. Moreover, low rigidity of collagen gel induced activation of ƒÝ-calpain. However, activation of ƒÝ-calpain was not involved in the formation of autophagy or degradation of c-Jun. Taken together, low rigidity induces an increase in [Ca++]i and triggers formation of autophagy which contributes to delay low rigidity-induced apoptosis mediated by c-Jun degradation.
²Ä¤G³õ¬¡°Êªáµ¶
¡i°ò¦Âå¾Ç¬ã¨s©Ò¤@¦~¯Å±i¤åøʦP¾Ç°T¡j
²âÅ¥§¹¤@³õ¥Í²z¾Ç±Ð±ÂªººtÁ¿¡A¼W¥[¤F§Ú¤@¨Ç¤£¦PÆ[©À¡AÄ´¦p:ì¥ý¥H¬°²ÓM¾i¦b°ö¾i¥×¤W¡A¨ä¥~§Îªº§ïÅÜ¥u¬O¦]¬°»Ýn¶Kªþ¡A©Ò¥H«¬ºA¤W¤~¦³©Ò¤£¦P¦Ó¤w¡A¸g¹L³o³õÁ¿z¡A©ú¥Õ¨ì²ÓMªº°ö¾i»P°ö¾i°ò¤§³nµw¬O¦³¬YºØµ{«×¤Wªº¼vÅT¡A¨Ã«D©Ò¦³°ö¾i°ò³£¾A¦X²ÓMªº¥Íªø¡A²ÓM¥~§ÎªºÅܤƤ]¬O©Î¦h©Î¤Ö¼vÅT¨ì¨ä¤§¶¡°T¸¹ªº¶Ç»¼¡I¹ïºÓ¤h¯Z¬ã¨s¥Í¦Ó¨¥¡A¯à¤O¸g¾ú©|¥¼¦¨¼ôÁÙ¬O³B©ó¾Ç²ß¶¥¬q¡A¤]¥u¯à°µ¤@¨Ç«ü¾É±Ð±Â¥æ¥Iªº¹êÅç¡AÃø§K¦³®ÉÔ·|¸j¤â¸j¸}¡AY¦³¤@¤Ñ¯à¼g¥X¤@¶µ¦Û¤vªº¹êÅçpµe¡A«ö·Ó¿³½ì¤èªk¥h¦Û¥Ñµo´§¬O¥ó¦h»ò´Îªº¨Æ¡A°µ¬ã¨s´N¬On¾Ç²ß»P³Ð³y·s¨Æª«¡I
|
|
ð¼w¦¨±Ð±Â |
ð¼w¦¨±Ð±Â»P¦Ñ®v®y½Í |
|
|
²{³õ¦Ñ®v»P¾Ç¥Í¿ãÅDÅ¥Á¿ |
Á¿®y»P¾Ç¥Í®y½Í |
²Ä¤T³õ¡Gð¼w¦¨±Ð±Â: Cardio-Renal Syndrome in Hemodialysis¡Vthe Role of Microinflammation
®É¶¡¡G97¦~3¤ë17¤é¬P´Á¤12:00~14:30
Á¿®y¡Gð¼w¦¨±Ð±Â(¶§©ú¤j¾Ç¥Í²z©Ò©Òªø¡A¥_ºaµÇŦ¬ì¥D¥ô)
Á¿ÃD¡GCardio-Renal Syndrome in Hemodialysis¡Vthe Role of Microinflammation
ºtÁ¿ºKn¡G
Cardiovascular (CV) morbidity and mortality are unacceptably high in hemodialysis patients. Although traditional CV risk factors are highly prevalent in hemodialysis patients, they cannot fully account for the excessive rate of CV diseases in this population. Therefore, considerable efforts have been focused on ¡§nontraditional¡¨risk factors in these patients. Among the nontraditional risk factors
examined, inflammation (interrelated to insulin resistance, oxidative stress, and endothelial dysfunction) has been suggested to play a key role in the development of atherosclerosis. It is well established that inflammatory markers are very powerful predictors of high CV morbidity and mortality in hemodialysis patients. Signs of a sustained low-grade inflammation (microinflammation), such as increased levels of C-reactive protein (CRP), are present in the majority of hemodialysis patients, even in those who are in clinically stable condition. Possible causes of microinflammation include comorbid illness, uremic toxins, decreased clearance of inflammatory cytokines, volume overload, and hemodialysis-related factors such as bioincompatibility or impurity of dialysate. As the prevalence of inflammation varies considerably between study groups, genetic factors may also have an impact on
inflammation.
Successful management of inflammation may ameliorate the CV epidemic in hemodialysis patietns. However, the results of intervention studies aimed at the reduction of CV events in these patients have been disappointing. Treatment strategies that concomitantly modify multiple risk factors may be reqiured to improve poor outcome in hemodialysis patients. The molecular and cellular consequences of microbial contaminations reaching the blood stream across a dialysis membrane were postulated 20 years ago in the interleukin hypothesis. As a component of the malnutrition-inflammation-atherosclerosis (MIA) syndrome and a strong inducer of cardiovascular complications, inflammation is considered one of the most urgent problems in dialysis management today and anything that can improve the inflammatory status of dialysis patients should be seen as highly valuable. We conducted a prospective controlled study to evaluate the impact of dialysis fluid quality on important patient-related parameters by using Gambro Heat Disinfection system. In this talk, the major clinical effects of improved fluid quality in a number of inflammation-related indices will be shown. The relevant effects on nutritional parameters, anemia management, and CV outcome will also be discussed.
²Ä¤T³õ¬¡°Êªáµ¶
¡i°ò¦Âå¾Ç¬ã¨s©Ò¤@¦~¯Å¼Bà±´@¦P¾Ç°T¡j
°ê¥ß¶§©ú¤j¾Ç¥Í²z©Ò©Òªøº[¥_ºaµÇŦ¬ì¥D¥ôð¼w¦¨±Ð±Â©Ò¥DÁ¿ªºÃD¥Ø¬°¦å²G³zªR¤§¤ßµÇ¯gÔ¸s¡CÅ¥§¹ð±Ð±Âªº¬ã¨s³ø§i¦¬Ã¬¬Æ¦h¡Aµo²{¦å²G³zªR¯f¤H¦³³\¦h¨Öµo¯g¡A¨ä¤¤³Ì¥Dn¥Bȱo«µøªº¬O¤ß¦åºÞ¤è±ªº¨Öµo¯g¡A¬O¾ÉP¯f¤H¦º¤`ªº«n¦]¤l¡C¨ä¤¤¤]´£¨ì¦å²G³zªR¯f¤H·|¾ÉPÄY«ªº³h¦å¡A¦]¦¹¡A¥²¶·µ¹¤©¾A·íªºÅK¾¯¸É¥R¡A¨ä¬ã¨s³ø§i«ü¥XÅK¾¯¸É¥R¹L¶q¤Ï¦Ó¹ï¯f¤H³y¦¨®ñ¤ÆÀ£¤Oªº¶Ë®`¡C¥t¥~¡A¨ä¬ã¨sÃÒ¹ê¦å²G³zªR´Á¶¡¥H¤fªA¤è¦¡¸É¥Rºû¥L©RC¡A©Î±Ä¥Î¦³ºû¥L©RE½Õ¸`ªº³zªR½¤¤Î¥Íª«¬Û®e©Ê¨}¦nªº³zªR½¤¡A¬Ò¯à¦³®Ä±±¨î®ñ¤ÆÀ£¤Oªºµo¥Í¡C¦Ó¦å²G³zªR¯f¤H¦]¦b³zªR¹Lµ{¤¤¡A¨ä±µÄ²ªº³zªR»ö¾¹©Î¾ÉºÞ¥i¯à¦³µß¸¨²£¥Í¨Ã¥BÀHµÛ¦å²G¶i¤J¤HÅé«á¡A¤º¬r¯À´N·|¿E°_Å餺¨¾¿m¨t²Îªº³sÂê¤ÏÀ³¡A§Î¦¨·Lµoª¢¤ÏÀ³¡A³y¦¨¤@³s¦êªº¨Öµo¯g¡A¦]¦¹¡Að±Ð±Âªº¬ã¨s¤]µo²{Y¯à±N¦å²G³zªR¿é°tºÞ¶¡ªº³s±µºÞ¨Ï¥Î¼ö®ø¬r¡A½T¹ê¯à°÷°§C¤º¬r¯Àªº¶Ë®`¡A¤]¯à°§Cµoª¢ªº¦MÀI©Ê¡C¦]¦¹¡A¦å²G³zªR¯f¤H»Ýn¿n·¥ºÊ´ú¨Ã³B²z¨ä¼ç¦bµoª¢¡A¬O¤@¶µ¤Q¤À«nªº¤u§@¡AµM¦Ó¡A¯à°÷±N¬ã¨sµ²ªGÀ³¥Î¦b¯f¤H¨¤W¡A¥B¿n·¥°§C¨ä¤ß¦åºÞ¨Öµo¯g¡A¬O¬ã¨sªÌ³Ì²×ªº¥Øªº¡C
¡i°ò¦Âå¾Ç¬ã¨s©Ò¤@¦~¯Å±i¤åøʦP¾Ç°T¡j
µÇŦ¤è±¯e¯f¬O°ê¤H«Ü±`¨£ªººC©Ê¯e¯f¤§¤@¡A¥Ñ©ó¥Á±Ú©Ê¾ÉP¤j³°¡B¥xÆW¤H³£«Ü·R¦YÃÄ¡A¦³¯fªv¯f¨S¯f·í¸ÉÃĪºÆ[©À¡A³vº¥¦a¬~µÇ¤H¤f¶V¨Ó¶V¦h¡A¥H«e¬~µÇ¤¤¤ß¤j³¡¤À¬Oªþ¦bÂå°|¸Ì¡Aªñ´X¦~«o«Ü©ö¨£¨ì¬~µÇªº¶E©Ò¡IY¬O¨ì¬~µÇ¦a¨B¡A¨º¥Í¬¡«~½è´N¤£¤Ó¦n¤F¡A¤@¬P´Á±o¬~3~4 ¦¸¡A¥B¥i¯à¬O¬~²×¨¡A¦³¿úªº¯f¤H´N·|·Qn´«µÇ¡A²¾´Ó¤@Ó·sªº¡A¥\¯à¤]¥u¯àºû«ùÓ¤Q´X¦~¡A²×¨sÁÙ¬O·|¤Þµo¨ä¥L¤ß¦åºÞ¯e¯f¦Ó¦º¤`¡A¤j³¡¤À¤H»{¬°´«µÇ´N¨S°ÝÃD¡A¦ý®Ú¾Ú¬ã¨s¬~µÇ»P´«µÇªº¦º¤`²v¬OµL©úÅã®t²§¡A³oÓµ²ªG¥i¥H§i¶D§ÚÌ¡A¤d¸U§OÅý¦Û¤v¯f¦¨³oӼˤl¡A©Ò¿×¹w¨¾³Ó©óªvÀø¡An¬¡´Nn°Ê°Ú¡I
¬¡°Ê¹w§i
2008 International Conference on Biomedicine & Graduate Student Retreat of Medical College in China Medical University
ªY³{¾Ç®Õ¤¤Q¶g¦~®Õ¼y¡AÂå¾Ç°|¦U¬ã¨s©Ò¤Î¾Ç³N¥æ¬y¤¤¤ß©ó5/1¤é(¬P´Á¥|)¤Î5/2¤é(¬P´Á¤)Áp¦XÁ|¿ì<2008 International Conference on Biomedicine & Graduate Student Retreat>¤Î°ò¦Âå¾Ç¬ã¨s©Ò®Õ¤Í¦^®Q®a¬¡°Ê¡F¥»¬ã°Q·|¤wÁܽЬü°ê¡B¤é¥»¡B·s¥[©Y¡B»´ä¡B¥xÆW¾ÇªÌºtÁ¿¡A¥t¤]±N®i¥X¥Íª«Âå¾Ç¬ã¨s¬ÛÃö»â°ì¤§¾À³ø½×¤å¡A¦]¦¹¡A·qÁܤj®a¿ãÅD°Ñ¥[¤Î§ë½Z¡A¤@¦PÅw¼y¤¤°êÂå¤j¥Í¤é§Ö¼Ö¨Ã¤À¨É³o¥÷³ß®®¡C
·|ij®É¶¡¡G97¦~5¤ë1¤é¡]¬P´Á¥|¡^¤W¤È8:10~¤U¤È17:00
97¦~5¤ë2¤é¡]¬P´Á¤¡^¤W¤È8:30~¤U¤È18:00
·|ij¦aÂI¡G¤¤°êÂåÃĤj¾Ç¥ß¤Ò±Ð¾Ç¤j¼ÓB1°ê»Ú·|ijÆU¡]40402¥x¤¤¥«¥_°Ï¾Ç¤h¸ô 91¸¹¡^
¥D¿ì³æ¦ì¡G¤¤°êÂåÃĤj¾ÇÂå¾Ç°|°ò¦Âå¾Ç¬ã¨s©Ò¡B¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡B¾Ç³N¥æ¬y¤¤¤ß
¨ó¿ì³æ¦ì¡G¤¤°êÂåÃĤj¾ÇÂå¾Ç°|¦U¬ã¨s©Ò
·|ij¬ÛÃö¤º®e¡J
¤@¡B¤j·|¯S§OºtÁ¿¡G97¦~5¤ë1¤é¡]¬P´Á¥|¡^¤W¤È8:10~¤U¤È5:00
±NÁܽЬü°ê¡B¤é¥»¡B·s¥[©Y¡B»´ä¡B¥xÆW¾ÇªÌ¯S§OºtÁ¿¡C
¤G¡B±MÃDºtÁ¿¡G97¦~5¤ë2¤é¡]¬P´Á¤¡^¤W¤È8:10~¤U¤È12:00
®Õ¤Í¡B°ò¦Âå¾Ç¬ã¨s©Ò¡B¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò±MÃDºtÁ¿
¡]³ø§i20¤ÀÄÁ¡A°Q½×10¤ÀÄÁ¡^
¤T¡B¬ã¨s¥Í¦¨ªGµoªí·|¡G97¦~5¤ë2¤é¡]¬P´Á¤¡^¤U¤È13:30~¤U¤È18:00
1¡B°ò¦Âå¾Ç¬ã¨s©Ò¬ã¨s¥Í¬ã¨s¦¨ªG¤fÀY³ø§i¡]³ø§i10¤ÀÄÁ¡A°Q½×5¤ÀÄÁ¡^¡C
2¡B°ò¦Âå¾Ç¬ã¨s©ÒºÓ¤G¬ã¨s¥Í¤@²v°Ñ¥[¡C
3¡B¤fÀY½×¤å¼úÀy¡G²Ä¤@¦W5000¤¸¡B²Ä¤G¦W4000¤¸¡B²Ä¤T¦W3000¤¸¡B²Ä¥|¦W2000¤¸¡B²Ä¤¦W1000¤¸
¥|¡B¾À³ø½×¤å³ø§i¡G97¦~5¤ë1¤é~5¤ë2¤é
1¡B®i¥Ü2¤Ñ¡C
2¡B¾À³ø½×¤å¼úÀy¡GºÂ¿ï5¦W¡A¨C¦W¦U1000¤¸¡C
¤¡B¥»¬ã°Q·|§K¶O°Ñ¥[¨Ãµo¥X®uÃÒ©ú®Ñ¡C
¤»¡B³ø¦W¤é´Á¡G¬°½T©w°Ñ»P¤H¼Æ½Ð©ó4¤ë28¤é¶ñ§´³ø¦Wªí¡A³ø¦Wªí½Ð¦Ühttp://www2.cmu.edu.tw/~cmcmg¤U¸ü¡A¨ÃE-mail¦Üaca66@mail.cmu.edu.tw¡C
¼x½Z³W«h¡G
¤@¡B¼x½Z¹ï¶H¡GÅwªï°ê¤º¥~¾Ç³N¬É¤Î¬ã¨s¤Hû§ë½Z¡C
¤G¡B½×¤åµoªí§Î¦¡¡G¾À³ø½×¤å(±i¶K®æ¦¡¬°90 cm¼e¡Ñ 120 cm°ª)¡C
¤T¡B¼x½Z½d³ò¡GÁ|¤Z¦³¥Íª«Âå¾Ç¬ÛÃö»â°ì§¡¥i§ë½Z¡A½Z¥ó¥H^¤å©Î¤¤¤å¼¶¼g¬°¡C
¥|¡B¼x½Z¤é´Á¡G¦Ü97¦~4¤ë24¤é¤î¡C
¤¡B§ë½Z¤è¦¡¡G©ó³W©w®É¶¡¤º±N¹q¤lÀÉ®×(WordÀɤÎpdf.ÀÉ¡A¨âºØÀɮ׮榡¬Òn)±H¦Ü aca66@mail.cmu.edu.tw¡AÀɮצWºÙ½Ðµù©úÁpµ¸ªÌ©m¦W¡C
¤»¡B½Z¥ó®æ¦¡ª`·N¨Æ¶µ¡GºKn¤º®e¤¤^¤å¬Ò¥i¡AºKnÃD¥Ø¤§¦U^¤å²Ä¤@Ó¦r¥À§¡¬°¤j¼g¡C¥H¼Ð·¢Åé©ÎTimes New Roman 12¸¹¦r¬°©y¡A¦æ»P¦æ¶¡¬°single space¡A¤º®e¥H¤@¶¬°¡C§@ªÌ¥H¤¤^¤åªí¥Ü¡A¨ä±Æ¦C§¡¬°¦W¦b«e¡A©m¦b«á¡A©m¦W¤U¤è¥[¹º©³½u¡C¥D³ø§iªÌ¦b¨ä©m¤§«áªþ¥[¡§¡¡¨¡A³d¥ô§@ªÌ¦b¨ä©m¤§«áªþ¥[¡§¡¯¡¨¸¹¡C
¤C¡B¦p¦³¥ô¦ó°ÝÃD½ÐÁpµ¸¡G(04)22053366Âà2201³¯¤p©j©Î(04)22053366Âà2268Á¨Χ»¦Ñ®v
E-mail¡Gaca66@mail.cmu.edu.tw¡Aºô§}http://www2.cmu.edu.tw/~cmcmg/
¤K¡BÅwªï¤j®a¿ãÅD§ë½Z¡C
°ò¦Âå¾Ç¬ã¨s©Ò ·qÁÜ
2008 International Conference on Biomedicine & Graduate Student Retreat of Medical College in China Medical University |
May 1-2, 2008, Taichung, Taiwan |
Conference Program |
Day one: Thursday, May 1, 2008
Lecture in English
Location: B1 International Conference Room, China Medical University, Taichung, Taiwan |
|
Time |
Topic |
Speaker |
Moderator |
|
08:10¡V08:30 |
Registration |
|
08:30¡V08:40 |
Opening Remarks |
Dr. Jong-Tsun Huang (Professor & President, China Medical University Taichung, Taiwan)
Dr. Wu-Chung Shen
(Organizing Committee Chair, Professor & Dean, College of Medicine China Medical University)
|
|
Session I |
|
08:40¡V09:20 |
Detection and Treatment of Hypertension: 50 Years of Progress |
Dr. Donald Dipepte
(Professor &Vice President , University of South Carolina) |
Dr. Chih-Yang Huang
(Professor & Director,Graduate Institute of Basic Medical Science,China Medical University )
|
|
09:20-10:00 |
Molecular Medicine- Putting Theory to Practice |
Dr. Jiahuan Ding
¡]Associate Professor, Institute of Biomedical Studies,Baylor University¡^ |
Dr. Lih-Jyh Fuh
(Associate Professor & Dean, School of Dentistry, China Medical University ) |
|
10:00-10:10 |
Q &A |
|
10:10-10:30 |
Coffee Break |
|
10:30-11:10 |
Recent Trends of Researches on the Chronic Kidney Disease Program in Taiwan |
Dr. Hui-Fang Li
(Professor , Georgetown University and Academia Sinica) |
Dr. Chih-Yang Huang |
|
11:10-11:50 |
Radionuclide Imaging in Oncology in the Era of Molecular Imaging |
Dr. Ren-Shyan Liu
¡]Professor , Department of Nuclear Medicine Faculty of Medicine National Yang-Ming University¡^ |
Dr. Wu-Chung Shen |
|
11:50-12:00 |
Q &A |
|
12:00-13:30 |
Lunch |
|
Session II |
|
13:30-14:00 |
A traditional herbal medicine prevents signaling disorders in gastric smooth muscle of diabetic rats |
Dr. Yasushi Sakai
(Physiol. & Pharmacol, Bunkyo University, Tokyo, Japan) |
Dr. Chiu-Yin Kwan
(Professor & Director, Center for International Affairs China Medical University) |
|
14:00-14:30 |
Novel vascular effects of perivascular adipose tissue |
Dr. Chiu-Yin Kwan
(Basic Med. Sci. Res. Institute, China Medical University Taichung, Taiwan) |
Dr. Chiu-Yin Kwan |
|
14:30-14:40 |
Q &A |
|
14:40-15:10 |
DCIP mediates TNF-alpha-stimulation of human lung fibroblasts |
Dr. WS Fred Wong
(Pharmacology, National University of Singapore) |
Dr. Chieh-Hsi Wu
(Professor & Director, Graduate Institute and School of Pharmacy, China Medical University) |
|
15:10-15:30 |
Anti-inflammatory effects of andrographolide in a mouse asthma model |
Dr. Bao Zhang
(Pharmacology, National University of Singapore) |
Dr. Chieh-Hsi Wu |
|
15:30-15:40 |
Q &A |
|
15:40-15:50 |
Coffee Break |
|
15:50-16:20 |
TRPC1 associates with BKCa channel to form a signal complex in vascular smooth muscle cells |
Dr. Xiao-Qiang Yao
(Physiology, Chinese University of Hong Kong) |
Dr. Ming-Chei Maa
(Professor &Director, Graduate Institute of Molecular systems Biomedicine, China Medical University ) |
|
16:20-16:40 |
Potentiation of TRPC5 channel activity by isoflavone genistein |
Mr. Ching-On Wong
(Physiology, Chinese University of Hong Kong) |
Dr. Ming-Chei Maa |
|
16:40-16:50 |
Discussion |
Dr. Chih-Yang Huang
Dr. Chiu-Yin Kwan
Dr. Ming-Chei Maa
Dr. Lih-Jyh Fuh |
|
17:00~ |
Symposium Dinner |
|
Organizer: Graduate Institute of Basic Medical Science, Graduate Institute of Molecular Systems Biomedicine, Center for International Affairs
Co-organizer: Graduate Institutes in College of Medicine
Tel:(04)22053366 ext.2201 E-mail:aca66@mail.cmu.edu.tw |
2008 ¤¤°êÂåÃĤj¾Ç Âå¾Ç°| °ò¦Âå¾Ç¬ã¨s©Ò ®Õ¤Í¦^®Q®a¤Î¬ã¨s¥Í¦¨ªGµoªí·|
|
®É¶¡¡G2008¦~5¤ë2¤é¬P´Á¤ 08:30~18:00 ¦aÂI¡G¥ß¤Ò¤j¼ÓB1°ê»Ú·|ijÆU |
Time |
Topic |
Speaker |
Moderator |
08:30¡V08:40 |
Registration |
08:40¡V08:50 |
Opening |
¨H¥³©¾ °|ªø¡]Âå¾Ç°|¡^
¶À§Ó´©Òªø¡]°ò¦Âå¾Ç¬ã¨s©Ò¡^ |
Session I |
08:50~09:20 |
¤À¨É¨D¾Ç¸gÅç¤Î±q¨Æ¬ã¨s¤§¥ÌW½Í |
·¨®aªY ®Õ¤Í
¡]¤¤°êÂåÃĤj¾ÇÂå¾Ç°|Âå¾Ç¨tÃIJz¾Ç¬ì¡^ |
Áé´º¥ú ±Ð±Â
¡]¥Íª«¬ì§Þ¨t¥D¥ô¡^ |
09:20¡V09:50 |
¤À¨É¨D¾Ç¸gÅç¤Î¨D¾¤§¥ÌW½Í |
®}Pªâ ®Õ¤Í
¡]ªi¥K¯S¥Íª«¬ì·~°È¸g²z¡^ |
Áé´º¥ú ±Ð±Â
¡]¥Íª«¬ì§Þ¨t¥D¥ô¡^ |
09:50-10:20 |
¶Àª÷¯ëªº®É¶¡°µ¥X¶Àª÷¯ëªº¨Æ |
¿à°û¤å ®Õ¤Í
¡]¤¤¤sÂå¾Ç¤j¾ÇÂå¾Ç¬ã¨s©Ò³Õ¤h¯Z¡^ |
Áé´º¥ú ±Ð±Â
¡]¥Íª«¬ì§Þ¨t¥D¥ô¡^ |
10:20¡V10:30 |
Coffee Break |
Session II |
10:30¡V10:50 |
High temporal resolution TKGFP fusion reporter gene for use in translational molecular-genetic imaging |
Á¨Χ» ¦Ñ®v
¡]°ò¦Âå¾Ç¬ã©Ò¡^ |
°¨©úµX ©Òªø
¡]¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡^ |
10:50-11:20 |
Bioinformatics approaches for sequence analysis |
±iÅVÄË ¦Ñ®v
¡]¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡^ |
°¨©úµX ©Òªø
¡]¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡^ |
11:20¡V11:50 |
®Õ¤Í»P¾Ç¥Í¤Î¦Ñ®v®y½Í(¤À¨É¨ä¨D¾Ç¸gÅç) |
11:50-13:30 |
Lunch & Posters |
Session III |
13:30¡V15:10 |
10¦ì¬ã¨s¥Í¦¨ªG³ø§i |
Á¹Ŭ ©Òªø
¡]Àù¯g¥Íª«¾Ç¬ã¨s©Ò¡^ |
15:10¡V15:20 |
Break & Posters |
15:20¡V17:00 |
10¦ì¬ã¨s¥Í¦¨ªG³ø§i |
°¨©úµX ©Òªø
¡]¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡^ |
17:00-17:50 |
6¦ì¬ã¨s¥Í¦¨ªG³ø§i |
§d¿üª÷ ¥D¥ô
¡]Âå¾Ç¨t¡^ |
17:50¡V18:00 |
Discussion |
°¨©úµX ©Òªø
¡]¤À¤l¨t²Î¥Íª«Âå¾Ç¬ã¨s©Ò¡^ |
Conference Chair¡G¨H¥³©¾ °|ªø Conference co-Chair¡G¶À§Ó´±Ð±Â¡B°¨©úµX±Ð±Â
Advisory Committee¡G°¨©úµX±Ð±Â¡B§d¿üª÷°Æ±Ð±Â¡BÁ¹Ŭ°Ʊб¡B³¯®®¥Í±Ð±Â¡B§õ«H¹F°Æ±Ð±Â
Program Committee Members¡GªL¤l®¦±Ð±Â¡BÃö¶WµM±Ð±Â¡BªL»ô±j±Ð±Â¡B±iÅVÄ˦Ѯv¡B¤ý±Ò¥ò¦Ñ®v¡BÁ¨Χ»¦Ñ®v¡B³¯¼zÔЦѮv¡B
±i¾¤¤ª¦Ñ®v
¤u§@ªA°È¹Î¶¤¡J¾Ç³N²Õ¡J¤ý±Ò¥ò¦Ñ®v ¾À³ø²Õ¡JÁ¨Χ»¦Ñ®v ¤½Ãö²Õ¡J±iÅVÄ˦Ѯv ¤å®Ñ²Õ¡J ³¯¼zÔЦѮv¡B±i¾¤¤ª¦Ñ®v
Á`°È²Õ¡J Âå¾Ç°|¦P¤¯
¦p¦³¥ô¦ó°ÝÃD½ÐÁpµ¸(04)22053366-2201 E-mail:aca66@mail.cmu.edu.tw |
¡@
|
|
|
|
¡i±Ð®v°ö¨|¶é¦a¡j |
¬¡°Ê¹w§i |
¡@³ü¡BE¤Æ±Ð¾Ç¨t¦CÁ¿®y¤G¡G¡u¼Æ¦ì±Ð§÷»s§@¹ê°È¬ã²ß·|¡v
¤@¡B¥D¦®¡G¼Æ¦ì±Ð§÷»s§@¹ê°ÈÀ³¥Î¡C
¤G¡B®É¶¡¡G¥Á°ê97¦~4¤ë16¤é¬P´Á¤T ¤U¤È1®É30¤À¦Ü5®É
¤T¡B¦aÂI¡G¤¬§U¤j¼Ó7¼Ó²Ä¤G¹q¸£±Ð«Ç
¥|¡B¥D¿ì³æ¦ì¡G±Ð®v°ö¨|º[µo®i¤¤¤ß¡B³qÃѱШ|¤¤¤ß
¤¡B°Ñ¥[¹ï¶H¡G¥»®Õ±Ð®v ¡]ÃB50¦W¡A³õ¦a¨î¡^
¤»¡B¬ã²ß¤º®e¡GAdobe captivate 3¤ÎMicrosoft Office 2003 power pointªº±Ð§÷»s§@¡C
«e1¤p®É¬°§âPower Point »s§@¬°¼Æ¦ì±Ð§÷ªº¤èªk¡A«á1¤p®É¬°
Captivate µ²¦Xpower pointªº±Ð§÷»s§@¡C
¤C¡Bijµ{º[³ø¦W¸ê°T¡G½Ð¤WCFD½u¤W³ø¦W¨t²Î³ø¦W
http://webap.cmu.edu.tw/cfd/Apply.asp
¡]½Ð©ó4¤ë14¤é«e§¹¦¨³ø¦W¡^
¤K¡BÁpµ¸¤H¡G±Ð®v°ö¨|º[µo®i¤¤¤ß ¶À©[°ï ¥ý¥Í ¤À¾÷¡G1622
³qÃѱШ|¤¤¤ß ®}¬Â¬À ¤p©j¡B³¯§gµÓ ¤p©j ¤À¾÷¡G1801
¤E¡B¥»¬ã²ß±Nµn¿ý±Ð®v¬ã²ß¿n¤À1¤À¡]±M¥ô±Ð®v½ÐÄâ±a±Ð®v¦¨ªøÅ@·Ó¡^
¡@¶L¡B¼Æ¦ì¾Ç²ßªº°ê»ÚÆ[»Pµo®iÁͶհê»Ú¬ã°Q·|
¤@¡B¥D¦®¡G¬°¨Ï±Ð®v̤F¸Ñ²{¤µ¼Æ¦ì¾Ç²ßªºÀ³¥Î»PÁͶաA¨Ã¼W¥[»P°ê»Ú¥æ¬y»P¸gÅç¤À¨É¡A©ó¤E¤Q¤»¦~¾Ç¦~«×²Ä¤G¾Ç´ÁÁ|¿ì¡u¼Æ¦ì¾Ç²ßªº°ê»ÚÆ[»Pµo®iÁͶաv°ê»Ú¬ã°Q·|¡A§Æ±æ¯à°÷¨Ï±o¥»®Õ±Ð®v̤F¸Ñ¼Æ¦ì¾Ç²ß²{¤µµo®iÁͶաA¨Ã½Ð°ê¥~¾ÇªÌDr. Marek Hatala»P¤¤¥¡¤j¾Ç¼Æ¦ì¾Ç²ß°ê®a¿ì¤½«Ç³¯°ê´É±Ð±Â¡AÅý°Ñ»PªÌ¦³§ó¶i¤@¨Bªº»{ÃÑ¡A¼W¥[¥þ®Õ®v¥Í¹ï©ó¼Æ¦ì¾Ç²ß§ó¥[¤F¸Ñ¡A´£°ªÀ³¥Î©ó¼Æ¦ì¾Ç²ß¥¥xªº¼Æ¦ì¤Æ±Ð¾Ç¡C
¤G¡B®É¶¡¡G¥Á°ê97¦~4¤ë29¤é¬P´Á¤G ¤W¤È9®É¦Ü¤U¤È1®É
¤T¡B¦aÂI¡G¥ß¤Ò±Ð¾Ç¤j¼Ó105¼Æ¦ì±Ð«Ç
¥|¡B¥D¿ì³æ¦ì¡G±Ð¾Ç¨ô¶V¿ì¤½«Ç
¤¡B¨ó¿ì³æ¦ì¡G³qÃѱШ|¤¤¤ß¡B±Ð®v°ö¨|º[µo®i¤¤¤ß
¤»¡B°Ñ¥[¹ï¶H¡G¤j±M°|®Õ±Ð®v¡B¥»®Õ®v¥Í
¤C¡Bijµ{º[³ø¦W¸ê°T¡G½Ð¤WCFD½u¤W³ø¦W¨t²Î³ø¦W
http://webap.cmu.edu.tw/cfd/Apply.asp
¡]½Ð©ó4¤ë25¤é«e§¹¦¨³ø¦W¡^
¤K¡BÁpµ¸¤H¡G³qÃѱШ|¤¤¤ß ®}¬Â¬À ¤p©j¡B³¯§gµÓ ¤p©j¡B®}¨Î¥Á ¥ý¥Í
¤À¾÷¡G1801¡B1819
±Ð®v°ö¨|º[µo®i¤¤¤ß ¶À©[°ï ¥ý¥Í ¤À¾÷¡G1622
¤E¡B¥»¬ã²ß±Nµn¿ý±Ð®v¬ã²ß¿n¤À1¤À¡]®Õ¤º±M¥ô±Ð®v½ÐÄâ±a±Ð®v¦¨ªøÅ@·Ó¡^
¡@°Ñ¡B¡u¸ê°T¯À¾i¿Ä¤J³qÃѱоǡG²z©À»P¹ê½î¡v°ê»Ú¬ã°Q·|
¤@¡B¥Øªº¡G¸ê°T¯À¾i¿Ä¤J³qÃѱоǡC
¤G¡B¥D¿ì³æ¦ì¡G±Ð¨|³¡¡B¤¤°êÂåÃĤj¾Ç³qÃѱШ|¤¤¤ß¡B±Ð®v°ö¨|º[µo®i¤¤¤ß
¤T¡B®É¶¡¡G97¦~5¤ë9¤é¡]¬P´Á¤¡^09:00-17:20
¥|¡B¦aÂI¡G¥»®Õ¤¬§U¤j¼Ó11¼Ó11A01±Ð«Ç
¤¡B°Ñ¥[¹ï¶H¡G¥þ°ê¤j±M°|®Õ±Ð®v
¤»¡Bijµ{º[³ø¦Wºô§}¡Ghttp://webap.cmu.edu.tw/cfd/Apply.asp
¡]½Ð©ó5¤ë5¤é«e§¹¦¨³ø¦W¡^
¤C¡B·|«á±N®Öµo7¤p®É¬ã²ßÃÒ©ú¡]±M¥ô±Ð®v½ÐÄâ±a±Ð®v¦¨ªøÅ@·Ó®Ö³¹¡^
¤K¡BÁpµ¸¤H¡G³qÃѱШ|¤¤¤ß ®}¬Â¬À ¤p©j¡B³¯§gµÓ ¤p©j ¤À¾÷¡G1801
±Ð®v°ö¨|º[µo®i¤¤¤ß ¶À©[°ï ¥ý¥Í ¤À¾÷¡G1622
¡@¸v¡B¤¤°Ï¤¤¶¥¥Í©RÛ²z¾ÇºØ¤l®v¸ê°ö°V¤u§@§{
¤@¡B¥D¦®¡G¥»½Òµ{¥Dn´£¨Ñµ¹¦U¤j±M°|®Õ¡BÂåÀø°|©Ò°ö°V¥Í©RÛ²z¾ÇºØ¤l®v¸ê¤§¬ã²ß¡A½Òµ{Äݤ¤¶¥¤º®e¡A¤D¨Ì¾Ú96¦~«×ªì¶¥¥Í©RÛ²z¾ÇºØ¤l®v¸ê°ö°V¤¤¾Çû½Ò«á¦^õX·N¨£¦Ó³]p¡C¥Øªº¬O¥H¥Ø«eÂåÀø¹ê°È¤¤³Ì¦³§xÂZ¤§Û²zijÃD¡AÂǥѺtÁ¿¡B¤Þ¨¥»P®y½Í¤è¦¡¡A°µ¬ÛÃö¤ÀªR©Mºc«ä¥H²¨¸ÑÛ²z¹ê°È§xÂZ¡A°ö¾i¾Çû¿W¥ß«ä¿ë¤Î³B²zÂåÀøÛ²zª§Ä³ªº¯à¤O¡A¨Ã¨ã¦³¥D«ùÛ²z°Q½×¤Î±q¨ÆÁ{§É³õ°ìÛ²z±Ð¾Ç¤§¯à¤O¡C½Òµ{µ²§ô¼f®Ö²Å¦X»{ÃÒ¸ê®æªÌ±N±Â¤©ÃҮѤξǤÀÃÒ©ú¡C
¤G¡B®É¶¡¡G¥Á°ê97¦~5¤ë10¤é¬P´Á¤»¦Ü6¤ë21¤é¡]¤À¥|¤Ñ½Òµ{¡A¨C¤Ñ¨â³æ¤¸¡^
¥»¦¸½Òµ{¬°5¤ë10¤éA¡BB³æ¤¸¡]¨Ì³æ¤¸³ø¦W¡^¡C
¤T¡B¦aÂI¡G¥ß¤Ò±Ð¾Ç¤j¼Ó6¼Ó²Ä¤@·|ij«Ç
¥|¡B¥D¿ì³æ¦ì¡G±Ð®v°ö¨|º[µo®i¤¤¤ß¡B¥xÆW¥Í©RÛ²z¾Ç·|¡B¥xÆWªÀ·|§ï³y¨ó·|¡C
¤¡B°Ñ¥[¹ï¶H¡G¥»®Õ±Ð®v¡B¤¤³¡¦a°Ï¦U¤j±M°|®Õ¡BÂåÀø°|©Ò¤§ÂåÀø¬ÛÃö¤Hû¤Î©Ò
¦³¹ïÛ²z¦³¿³½ì¤§ªÀ·|¤H¤h¡C
¤»¡B³ø¦Wºô§}º[ijµ{¡G http://webap.cmu.edu.tw/cfd/Apply.asp¡]½Ð©ó½Òµ{¶}©l«e2
¤Ñ§¹¦¨³ø¦W¡^
¤C¡B½Òµ{¸ê°T¡G¥»°ö°V¦@¦³4¦¸½Òµ{¡A¨C¦¸½Òµ{¤À¬°2³æ¤¸¡A½Òµ{·í¤Ñ·|¨Ì·Ó°Ñ»P¤§®É¼Æµoµ¹®É¼ÆÃÒ©ú¡A¥H§¹¾ã³æ¤¸¬°®É¼ÆÃÒ©ú¤§°ò¥»pºâ³æ¦ì¡C¾Çû¥t¥i¥Ó½Ð¤½°È¤Hû²×¨¾Ç²ß¾Ç¤À¤Î½Ã¥Í¸pÂå¾ÇÛ²z¾Ç¤À¡C
¤K¡B»{ÃÒ¸ê®æ¡GÁ`½Òµ{µ²§ô®É¡A°Ñ»P³õ¦¸²Ö¿nº¡6³æ¤¸ªÌ¡A¾Çû¥²¶·¨Ì¥D¿ì³æ¦ì³W©w¡A¦Û¿ï¨â³æ¤¸Ãº¥æ«ü©w§@·~¡A¸g¾Ç·|¼f®Ö»{¥i¡A¥xÆW¥Í©RÛ²z¾Ç·|±N±Â»P¤¤¶¥¥Í©RÛ²z¾Ç½Òµ{ÃҮѡC
¤E¡B³ø¦W¶O¡G¥»®Õ¤Îªþ³]Âå°|§K¶O¡]ÃB¦³·q½Ð§â´¤¡A¬°ÅU¤Î±Ð®vÅv¯q¡A·q½Ð³ø¦WªÌ°È¥²¥X®u·í¤Ñ¬ã²ß¡AY³ø¦W¦Ó¥¼¥X®u¹F¨â¦¸¥H¤WªÌ±N¨ú®ø©¹«á³ø¦W¸ê®æ¡A³y¦¨¤£«K©|§Æ¨£½Ì!!¡^
¤Q¡BÁpµ¸¤H¡G±Ð®v°ö¨|º[µo®i¤¤¤ß ¶À©[°ï ¥ý¥Í ¤À¾÷¡G1622
¤Q¤@¡B¥þµ{°Ñ»P¤§¨Ó»«±N©ó¨C³æ¤¸®Öµo4¤p®É¬ã²ßÃÒ©ú¡]®Õ¤º±Ð®v½ÐÄâ±a±Ð®v¦¨
ªøÅ@·Ó¡^
¡@ |
|
|
E¤Æ±Ð¾Ç¨t¦CÁ¿®y¤@¡G¡uE¤Æ±Ð¾Ç¸ê·½¤§À³¥Î¡v |
|
|
¶}¹õPµü¡X±Ð®v°ö¨|º[µo®i¤¤¤ß ¨¯©¯¬Ã °Æ±Ð±Âݲժø |
±MÃDºtÁ¿¡X³qÃѱШ|¤¤¤ß ¹ùz²± ±Ð±ÂÝ¥D¥ô |
|
|
¬ã²ß®Éªp1 |
¬ã²ß®Éªp2 |
¡@¡i±Ð®v°ö¨|º[µo®i¤¤¤ß/¶À©[°ï °T¡j¬°¼W¶i¥»®Õ±Ð®v±Ð¾Çª¾¯à»P±M·~¦¨ªø¡A±Ð®v°ö¨|º[µo®i¤¤¤ß»P³qÃѱШ|¤¤¤ß¯S§O©ó97¦~4¤ë9¤é°_Á|¿ì¤@¨t¦C¡uE¤Æ±Ð¾Ç¨t¦CÁ¿®y¡v¡]½Ð°Ñ¨£Ä³µ{ªí¡^¡A¥»¦¸¬ã²ß¡]4¤ë9¤é¡^¦@40¦ì±Ð®v³ø¦W°Ñ»P¡]¦]³õ¦a¨î¬GÃB40¦ì¡^¡A¬ã²ß·í¤Ñ¬ÛÃö¥X®u·§ªp½Ð°Ñ¾\¤Uªí¡G
¾Ç°| |
³ø¦W¤H¼Æ |
¹ê¨ì¤H¼Æ |
¥X®u²v |
¤¤Âå¾Ç°| |
3 |
1 |
33% |
¤½¦@½Ã¥Í¾Ç°| |
0 |
0 |
0% |
¥Í©R¬ì¾Ç°| |
0 |
0 |
0% |
°·±d·ÓÅ@¾Ç°| |
9 |
5 |
56% |
Âå¾Ç°| |
8 |
7 |
88% |
Ãľǰ| |
21 |
17 |
81% |
Á`©M |
41 |
30 |
73% |
E¤Æ±Ð¾Ç¨t¦CÁ¿®y¬ã²ß¬¡°Ê
³õ¦¸ |
®É¶¡ |
¥DÃD |
¥DÁ¿ªÌ |
ªA°È³æ¦ì |
1 |
4¤ë9¤é
¡]¬P´Á¤T¡^ |
E¤Æ±Ð¾Ç¸ê·½¤§À³¥Î |
¹ùz²±
±Ð±ÂÝ¥D¥ô |
³qÃѱШ|¤¤¤ß |
2 |
4¤ë16¤é
¡]¬P´Á¤T¡^ |
¼Æ¦ì±Ð§÷»s§@¹ê°È |
®}¨Î¥Á §U²z |
³qÃѱШ|¤¤¤ß |
3 |
4¤ë23¤é
¡]¬P´Á¤T¡^ |
¼Æ¦ì±Ð§÷À³¥Î¹ê°È¤À¨É |
¥t¦æ¤½§i |
|
¥»¦¸¬ã²ß«Üºa©¯¯àÁܽШ쥻®Õ³qÃѱШ|¤¤¤ß¹ùz²±¥D¥ô»¡©ú¸û¬°¹ê¥Î¤§E¤Æ±Ð¾Ç¸ê·½¡A¹ù¥D¥ô¦CÁ|¥H¤U´XÓ¸ûª¾¦Wºô¯¸¨Ñ±Ð®v°Ñ¦Ò¡G
1. ¼Æ¦ì¾Ç²ßºô¯¸¡Ghttp://elearn.cmu.edu.tw/
2. GOOGLE SCHOLAR¡Ghttp://scholar.google.com/
3. WIKIPEDIA¡Ghttp://www.wikipedia.org/
4. MERLOT¡Ghttp://www.merlot.org/merlot/materials.htm
¸g¥Ñ¹ù¥D¥ô¹ê»Ú¾Þ§@¥B¸ÔºÉªº»¡©ú¡A¨ô¹êÅý°Ñ»P¬ã²ß¤§±Ð®vÀò¯qê²L¡C¦Ó¥»¦¸¬ã²ß¬°¤@¨t¦CÁ¿®y¤§¶}ºÝ¡A±Ð®v°ö¨|º[µo®i¤¤¤ß»P³qÃѱШ|¤¤¤ß±N¥t©ó4¤ë16¤é»P4¤ë23¤é¤À§O¿ì²z¨t¦C¬ã²ß¡]½Ð°Ñ¨£¤Wªí¡^¡A©¡®ÉÅwªï¦U¦ì¥DºÞ¡B±Ð®v»P§Ṳ́@¦P¦¨ªøºë¶i¡C
¡i¸ê®Æ¨Ó·½¡G±Ð®v°ö¨|º[µo®i¤¤¤ß¡j
¡@ |
|
¡i¨|¦¨¤¤¤ß¶é¦a¡j |
³Ð·s¨|¦¨·~°È |
¡@±Ð¾Ç¨ô¶Vpµe-¡u§Þ³N³Ð·~¸ó»â°ì¸g²z¤H¾i¦¨¾Çb¡v¼Ò²Õ¤@¡G¬ì§ÞºÞ²z°ö°V¯Z97¦~03¤ë06¤é½Òµ{¬¡°Ê¡G¡y¥i°Ó«~¤Æ§Þ³N¨Ó·½»P·j¶°¤èªk¡z¡B¡y§Þ³N±ÂÅv¤èªk»P¹ê°È¡z¡C
¡@ |
|
´¼¼z°]²£ÅvºÞ²zº[§Þ³N²¾Âà·~°È |
¡@1. ´¼¼z§½¨ó½ÕÂç²MµÛ¦W°Ó¼Ð¤Îªí¼x³Q«I®`¤§ªk«ß±ÏÀÙ³~®|
¬°¦^À³¼Ú¤è¥h¡]96¡^¦~10¤ë23¤é¡u²Ä19©¡¥x¼Ú·ù¿Ô°Ó´¼¼z°]²£Åv¤u§@¤À²Õ·|ij¡v¤¤©Ò´£¥X¡A§Ú¤è¦bµÛ¦W°Ó¼Ð«OÅ@µ¥Ä³ÃD¤W¡A°õªk¾÷Ãö¶¡¬O§_²M·¡¤À¤u¤Î·¾³qºÞ¹DºZ³q»P§_µ¥½èºÃ¡A¸gÀÙ³¡´¼¼z°]²£§½¡]¤UºÙ´¼¼z§½¡^©ó¤µ¡]97¡^¦~3¤ë14¤é¤W¤È¥l¶}¡uµÛ¦W°Ó¼Ð¤Îªí¼xªk«ß±ÏÀÙ³~®|¬ã°Q·|¡v¡A´N¼Ú¤è©ÒÃö¤Á¤§¨Æ¶µ»PµÛ¦W°Ó¼Ð¤Îªí¼x¾D«I®`®É¦p¦ó±Ä¨úªk«ß±ÏÀÙ³~®|µ¥Ä³ÃD¶i¦æ°Q½×¡C
¥»¦¸·|ij¥Ñ´¼¼z§½¤ý§½ªø¬üªá¥D«ù¡A¼Ú¬w¸g¶T¿ì¨Æ³B¡B¬ü°ê¦b¥x¨ó·|¡B¤é¥»¥æ¬y¨ó·|¤Î¼Ú¬w°Ó°È¨ó·|µ¥¾÷ºc§¡¨üÁܬ£û¥X®u¡C§Ú¤è¬F©²³¡ªù«h¦³¦æ¬F°|¤½¥¥æ©ö©eû·|¡]¤UºÙ¤½¥·|¡^¡B¸gÀÙ³¡°Ó·~¥q¡Bªk°È³¡¡B¦æ¬F°|¸gÀ٫س]©eû·|µ¥³æ¦ì¥ç¥X®u°Ñ»P°Q½×¡C
¦³Ãö¥HµÛ¦W°Ó¼Ð©Îªí¼x§@¬°¦Û¤v¤§¤½¥q¡B°Ó¸¹¦WºÙªº«I®`¦æ¬°ºA¼Ë¤W¡A¸gÀÙ³¡°Ó·~¥qªí¥Ü¡A¦p°Ó¼ÐÅv¤H¨Ì·Ó°Ó¼Ðªk²Ä62±ø³W©w¹ï©ó«I®`¦æ¬°¤H¨ú±o³Ó¶D½T©w§P¨M¡A¦Ó³Q§i©Úµ´¿ì²z¤½¥q¦WºÙÅܧóµn°O®É¡A¥Ø«e¨ÃµL¬ÛÃö³W½d¡A¥¼¨Ó¦Ò¼{¯Ç¤J¤½¥qªk²Ä10±ø³W©w¡A¼W¥[¤@´Ú©R¥O¸Ñ´²¨Æ¥Ñ¡A¥H¸¨¹ê°õ¦æ«OÅ@´¼¼z°]²£Åv¤§§P¨M¡C¼Ú¬w°Ó°È¨ó·|°£¤FªÖ©w§Ú¤è«OÅ@´¼¼z°]²£Åv¤§¥Î¤ß¡A¨Ãªí¥Ü¤½¥qªk°t¦X×¥¿¼W¥[©R¥O¸Ñ´²¨Æ¥Ñ¹ï©óµÛ¦W°Ó¼Ð¤§«OÅ@¨ã¦³¥¿±·N¸q¥~¡A¥ç§Æ±æ§Ú¤è¥DºÞ¾÷Ãö¯à°÷¦Ò¶q¦b®Ö㤽¥q¦WºÙµn°O¤§«e¯à¹w¥ý¼f®Ö¡AÁקK³y¦¨µn°O¤½¥q¦WºÙ»P¥L¤HµÛ¦W°Ó¼Ð¬Û½Ä¬ð¤§±¡§Î¡C
¨ä¦¸¡A¦bµÛ¦W°Ó¼Ð©Îªí¼x¥é«_®×¥óªº±ÏÀÙ³~®|¤è±¡A¤½¥·|¤§¥X®u¥NªíÁ|¶Â¤H¤ú»I»P¥Õ¤H¤ú»Iª§³^¹O10¦~¤§®×¨Ò¡A»¡©ú³z¹L¤½¥·|¥H¦æ¬F»@ªº¤è¦¡³B²z«I®`µÛ¦W°Ó¼Ð©Îªí¼xªº§@ªk¡A¦b«áÄò±ÏÀÙµ{§Ç¥u¯à¥Ñ³B¤À¾÷Ãö¤½¥·|ªí¹F¤ä«ù¤@³yªº¥ß³õ¡A¦Ó¹ê»Úª§Ä³Âù¤è·í¨Æ¤H¤ÏÂЪ§³^ªºµ²ªG¥u·|³y¦¨®É¶¡©ì©µ¡A¥¼¥²²Å¦X¨â³yªº¹ê½è§Q¯q¡C¤½¥·|¥Nªí¥ç±N¤½¥¥æ©öªk¡]¤UºÙ¤½¥ªk¡^²Ä20±ø»P²Ä24±ø©Ò³W©w«I®`µÛ¦W°Ó¼Ð©Î¤£¤½¥Ävª§¦æ¬°¡A¨¬¥H´£¨ÑÅv§Q¤H±ÏÀÙ¥D±iªº®×¨ÒÃþ«¬¤@¤@¥[¥H»¡©ú¡A¦P®É±´°Q¤½¥·|¨ü²z¸Óµ¥®×¨ÒÃþ«¬¦b¼f¬d¤W¤§§PÂ_«ÂI¡A¨Ã¨Ì·Ó¦UºØ¥i¯à«I®`µÛ¦W°Ó¼Ð©Îªí¼x¤§¦æ¬°ºA¼Ë¡A´£¨Ñ¹L¥h°Ó¼ÐÅv¤H¦V¤½¥·|´£¥XÀËÁ|©Î¦Vªk°|´£°_¶D³^¦Ó¦¨¥\¦æ¨Ï©ÎºûÅ@Åv¯q¤§¬ÛÃö®×¨ÒºKn¡A§@¬°Åv§Q¤H¤é«á¥D±iÅv§Q¤§°Ñ¦Ò¡C
°w¹ï°Ó¼ÐªkÃö©óÅv§Q«I®`¥Á¨Æ±ÏÀÙ»P¦D¨Æ»@«h³¡¤À¤§³W©w¡A»P¤½¥ªk²Ä20±ø¤Î²Ä24±ø³W©w«Å|¤§±¡§Î¡A¤½¥·|¥ç«¥Ó¡G¦pªG«I®`ªº¹ï¶H¬Oµù¥U°Ó¼Ð¦Ó¥B¯A¤Î°Ó¼Ðªk²Ä81±ø¦D¨Æ³d¥ô³¡¤À¡A¨Ì·Ó¦æ¬F»@ªk²Ä26±ø²Ä1¶µ³W©w¡u¦D¨ÆªkÀu¥ý¾A¥Î¦æ¬Fªk¡vì«h¡A¤½¥·|¤£¤¶¤J³B²z¡A±N²¾¥Ñ´¼¼z§½´`¦D¨Æ³~®|³B²z¡C¦¹¥~¡A¤é¥»¥æ¬y¨ó·|»P¼Ú¬w°Ó°È¨ó·|¹ï©ó¤½¥ªk×¥¿¯ó®×¬O§_±N§R°£¹ï©óµÛ¦W°Ó¼Ð©Îªí¼x«OÅ@¤§³W©w¡A¥çªí¹F°ª«×Ãö¤Á¤§·N¡C¹ï¦¹¡A¤½¥·|ªí¥Ü¡A×¥¿¯ó®×ªº½T¦³¨âºØ¥i¯àªº¤è®×¡A¨ä¤@¬°§R°£¤½¥ªk¬ÛÃö¦æ¬F³d¥ô¡A¶È«O¯d¥Á¨Æ½ßÀv³d¥ô¤§³W©w¡F¥t¤@ºØ«h«Y§¹¥þ§R°£¹ï©óµÛ¦W°Ó¼Ð©Îªí¼x«OÅ@¤§³W©w¡A¦^Âk°Ó¼Ðªk¨Ó³B²z¡AµM´N¦¹Ä³ÃD¤½¥·|¥Ø«e©|¥¼§@¦¨¬Fµ¦¨M©w¡CÅv§Q¤H¹ÎÅé«h§Æ±æ¥¼¨Ó¤½¥ªk×¥¿¤è¦V©w®×«á¡A¯à¹ï¥~¥l¶}¤½Å¥¡A¨Ï¥~¬É¦³À˵ø»Pªí¥Ü·N¨£¤§¾÷·|¡C
³Ì«á¡A¼Ú¬w¸g¶T¿ì¨Æ³B°Æ³BªøÂà¹F¼Ú¬wÁp·ù°õ¦æ©eû·|¹ï©ó´¼¼z§½¥l¶}¥»¦¸·|ij¡A¥H¤Î»P·|ªÌ¼ö¯P°Ñ»P°Q½×¡A¨Ã´£¨Ñ¨ãÅé¸ê®Æ»P¸Ñ¨M¤è®×µ¥§@ªkªí¥Ü·PÁ¤§·N¡C
2. ±M§Q¶D³^-¤p½¼¦Ì¹ï§Ü¤jÄH³½¦A¤@¨Ò
¸qµo¬ì§Þ°w¹ïµ§°O«¬¹q¸£¡]NB¡^IJ±±±ªOIC¥D°Ê¹ï·s«ä¿³³^¡A¾Ú¤F¸Ñ¡A³o³õ©x¥q쥻¤£¨ü¥~¸ê¡Bªk¤H¬Ý¦n¡A¨S·Q¨ì²©ö§P¨Mªºµ²ªG¬Û·í¥¿±¡A¶^¯}¥«³õ²´Ãè¡C
¥Ø«eNBIJ±±±ªOIC¥«³õ¡A·s«ä¥«³õ¥e¦³²v¹F70%¡A¨ä¦¸¬°¤é°ÓAlps¬ù25%¡B¬ü°Ó¶ë´¶©Ô´µ5%¡A¸qµo¶È3%¤£¨ì¡A¸qµo¥H¤p½¼¦Ì¹ï¤jÄH³½¤§«º§æË·s«ä¡A§ó½T©w¸q¶©¶°¹Î¥¼¨Ó¦b°ê¤ºÄ²±±±ªOICªº¥D¾É¦a¦ì¡C
°ê¤ºIC³]p·~ªÌ³o´X¦~¦b°ê»Ú¶D³^©x¥qÂA¤Ö³Ó¶D¡A°£¤F¦¦~«Â²±¦bP4¥¥x»P^¯Sº¸«IÅv¤§ª§¤jÀò¥þ³Ó¥~¡AIC³]pÀsÀYÁpµo¬ì¦´Á»P¾óµØ¡]OAK¡^ªº©x¥q¤]³Ó¶D¡C¤£¹L¡AÁpµo¬ì«á¨Ó¤S³s¾D¬ü°Ó»õ¥@¡]ESS¡^»P¨ôµM¡]Zoran¡^´£¥X«IÅv§i¶D¡A³Ì«á³£¥I¥X¤£¤ÖÅv§Qª÷¥H©M¸Ñ¦¬³õ¡A³o¦¸¸qµoÀò±oªì¨B¦nµ²ªG¡A¹ïªñ¦~°ê¤ºIC³]p¼t§Þ³N¤Wªº§V¤O¡A¦³¤@©wªºªÖ©w¡C
¸q¶©±q·L±±¨î¾¹¡]MCU¡^°_®a¡A¥h¦~¥¿¦¡¸ó¤JIJ±±±ªO»â°ì¡A¦¨¬°°ê¤ºIC³]p¤½¥q¦Ñ©±·s¶}ªº¥Í¤Ox¡AIJ±±±ªOÁöµM¨ü¾É¹q¬Á¼þ¨}²v§C¡B¨t²Î¦¨¥»¤´°ª¾ÉP©|¥¼¤j¶q´¶¤Î¡A«o¤£´î¸q¶©¹ï¦¹¤@»â°ìªº¥¬§½¥ø¹Ï¡C
¥Ø«e¸q¶©¦b¤â¾÷¡Bµ§¹q¡BUMPC¡BGPS»P¼Æ¦ì¬Ûµ¥®ø¶O¹q¤l³£¦³¤@©wµÛ¾¥¡A¦b§ë¸ê¸qµo¬ì§Þ«á¡AÁÙ»P¸qµo¦b«n¬ì¦¨¥ßITO¾É¹q¬Á¼þ¸q±j¬ì§Þ¡A¥ø¹Ï¥D¾É«e¬q§÷®Æ¡A¤]¬Ý±o¥X¤½¥q§Æ±æ¦bIJ±±±ªO¤@±øÃ@ªº¥ø¹Ï¡C
¡@ |
|
¬ÛÃö¬ã°Q·|¸ê°T |
- 96¦~04¤ë17¤é(¬P´Á¥|)¡A14:30 ~ 17:00¡A¡y±M§Qªk×¥¿¯ó®×(²{¦æªk¦³Ãö¹ê°È§@·~³¡¤À)²Ä4¦¸¤½Å¥·|¡z¡C¡]¸ê®Æ¨Ó·½¡G¸gÀÙ³¡´¼¼z°]²£§½¡Fºô¯¸¡Ghttp://www.tipo.gov.tw/service/news¡^
- 96¦~04¤ë22¤é(¬P´Á¤G)¡A09:00 ~ 12:30¡A¡y97¦~´¼¼z°]²£Åv·~°È®y½Í·|¡z¡C¡]¸ê®Æ¨Ó·½¡G¸gÀÙ³¡´¼¼z°]²£§½¡Fºô¯¸¡Ghttp://www.tipo.gov.tw/service/news¡^
|
|
¡i®½´Ú¶é¦a¡j |
®½´Ú©ú²Ó¡i®½´Ú´Á¶¡97.03.31~97.04.14¡j |
¡@¨ü®½³æ¦ì¡GÂå¾Ç¨t-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970331 |
¿à¥Ã¶© |
100,000 |
F30792 |
970402 |
¸«TÀà |
10,000 |
F40036 |
970402 |
¾G©÷ÀB |
5,000 |
F40034 |
¨ü®½³æ¦ì¡G¤¤Âå¨t-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970402 |
¦¿ºÖ¸q |
5,000 |
F40038 |
¨ü®½³æ¦ì¡G¾Ç¤h«á¤¤Âå¾Ç¨t-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970402 |
³¯¬f¥þ |
2,000 |
F40037 |
970402 |
³¯¬ü§g |
10,000 |
F40049 |
970408 |
³¯¥ß¼w |
50,000 |
F40098 |
¨ü®½³æ¦ì¡G¤¤°êÂå¾Ç¬ã¨s©Ò-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970407 |
±i¥@¨} |
20,000 |
F40071 |
¨ü®½³æ¦ì¡G¤úÂå¨t-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970402 |
¨H·ç¤å |
5,000 |
F40042 |
¨ü®½³æ¦ì¡GÃľǨt-¨È¤ÓÃľǷsª¾¬ã°Q·|
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970402 |
¨¿³·¬õ |
15,000 |
F40047 |
970407 |
¼b¥ÍªÑ¥÷¦³¤½¥q |
10,000 |
F40073 |
970408 |
ªø´¼¤å¤Æ¨Æ·~¦³¤½¥q |
15,000 |
F40099 |
970408 |
´ä»ÄõÃļtªÑ¥÷¦³¤½¥q |
15,000 |
F40094 |
970414 |
¥x¥ÐÃÄ«~(ªÑ)¤½¥q |
10,000 |
F40166 |
¨ü®½³æ¦ì¡GÃĪ«¤Æ¾Ç¬ã¨s©Ò-±Ð¾Ç¨ô¶V°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970408 |
¤ès²M |
10,000 |
F40110 |
¨ü®½³æ¦ì¡GÃľǨt¨t¾Ç·|ªÀ¹Î¬¡°Ê
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970408 |
°]¹Îªk¤H¥x¤¤¸t¹Ø®c |
5,000 |
F40093 |
970411 |
¥x¤¤¥«¤¸«O®cºÞ²z©eû·| |
2,000 |
F40154 |
¨ü®½³æ¦ì¡G®Õ°Èµo®i°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970401 |
¼yÂ׻Ȧæ¥x¤¤¤À¦æ |
1,323 |
F40025 |
970402 |
¶ÀÄR¼b |
400 |
F40035 |
970403 |
±iºû§g |
6,000 |
F40061 |
970408 |
¤×ºøºø |
500 |
F40111 |
¨ü®½³æ¦ì¡G¹Ï®Ñ°òª÷
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
970408 |
³¯¾Ëªk |
2,000 |
F40083 |
970410 |
§õ¤pÄ_ |
1,000 |
F40141 |
¨ü®½³æ¦ì¡G¥»®ÕªÀ¹Î¬¡°Ê
®½´Ú¤é´Á |
®½´ÚªÌ |
®½´Úª÷ÃB |
¦¬¾Ú½s¸¹ |
»¡©ú |
970402 |
«n¥ú¤Æ¾Ç»sÃĪѥ÷¦³¤½¥q |
5000 |
F40039 |
®õ¥_®LÆvªA°È¶¤ |
970402 |
´I¥Ð»sÃļtªÑ¥÷¦³¤½¥q |
1500 |
F40040 |
970403 |
©ú¼w®c¤Ñ¸t°óªþ³]©ú¼wª÷Äõ±ÏÀÙ·| |
5000 |
F40056 |
970408 |
°]¹Îªk¤H¥xÆW¬Ù¨p¥ß¤ý§õªÀ·|ºÖ§Q·Oµ½¨Æ·~°òª÷·| |
5000 |
F40084 |
970402 |
¸t½å°ó |
5000 |
F40044 |
ÂåÃÄ¥vªÀ |
970403 |
¤¤µØ¥Á°ê¤@³e¹DÁ`·| |
50000 |
F40060 |
970409 |
°]¹Îªk¤H¥xÆW¬Ù¨p¥ß¤ý§õªÀ·|ºÖ§Q·Oµ½¨Æ·~°òª÷·| |
5000 |
F40126 |
970411 |
¥x¤¤¥«¤¸«O®cºÞ²z©eû·| |
5000 |
F40153 |
¡i¸ê®Æ¨Ó·½¡G¶Ò®½©eû·|¡j
|
|
¡i¤½§i¨Æ¶µ¡j |
®Õ¤º¾Ç³N¬¡°Ê |
¡@¡@
¬¡°Ê/¤½§i¤é´Á |
¬¡°Ê¦WºÙ |
¤½§i³æ¦ì |
2008/4/2 |
Melanoma Research: From Natural History and Prognosis Studies to Clinical Trials and Model Building |
¥Íª«²Îp¤¤¤ß |
2008/4/3 |
°·±d·ÀIºÞ²z»P·¾³q¨t¦CÁ¿®y(¤T)-¹AÃļÉÅS·ÀIµû¦ô |
·ÀIºÞ²z¾Ç¨t |
2008/4/3 |
¥Õ¨¢§Q¤p«KªºÁ{§ÉÀ³¥Î |
¤¤ÂåÂå±Ð·| |
2008/4/9 |
Development of Biomarker Classifiers |
¥Íª«²Îp¤¤¤ß |
2008/4/10 |
¤úÂå±Ð¨|°ê»Ú»{ÃÒº[½Òµ{³]p¬ã°Q·| |
¤úÂå¨t |
2008/4/10 |
¤¤ÃĪº°ò¦]Åé¬ã¨s |
¤¤ÂåÂå±Ð·| |
2008/4/16 |
Statistical Tests for the Analysis of Environmental Toxicants |
¥Íª«²Îp¤¤¤ß |
2008/4/17 |
ªÍÀùªvÀø²{ªp |
¤¤ÂåÂå±Ð·| |
2008/4/24 |
¥xÆW¥«°â©ö²V²c¤¤ÃĤÎÅGÃÑ |
¤¤ÂåÂå±Ð·| |
|
|
®Õ¥~¾Ç³N¬¡°Ê |
¡@
¥_°Ï
¤¤°Ï
«n°Ï
ªF°Ï
°ê¥~
¡@ |
|
ªñ´Á¬¡°Ê°T®§ |
¡@
¡@ |
|
¼ú¾Çª÷°T |
¡@¤½§i³æ¦ì: ¾Ç³N¥æ¬y¤¤¤ß
¡@¤½§i³æ¦ì: ½Ò¥~¬¡°Ê²Õ
|
|
E§Ö³ø |
¡@
¡@ |
|
|